TRIM14

Across TCGA pan-cancer cohorts, TRIM14 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRIM14 data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TRIM14 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRIM14 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, GBM, and HNSC are the cancer types where TRIM14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.964	0.653	.001	41	view →
GBM	OS	Median	All	0.408	0.653	.003	29	view →
HNSC	OS	Quartile	III,IV	1.000	0.242	.024	22	view →
PDAC	OS	Median	III,IV	0.798	0.249	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TRIM14–CCRCC (DFS)

Open the CCRCC breakdown →